Table 2. Characteristics of infant hospitalisations with lower respiratory tract infections and nirsevimab immunisation status, stratified by respiratory syncytial virus (RSV) PCR results, three regions in Spain, October 2023–January 2024 (n = 166 admissions).
| Characteristics | Murcia (n = 107) | Valencia (n = 52) | Valladolid (n = 7) | ||
|---|---|---|---|---|---|
| Negative RSV-LRTI | RSV-LRTI | Negative RSV-LRTI | RSV-LRTI | RSV-LRTI | |
| n = 55 | n = 52 | n = 16 | n = 36 | n = 7 | |
| Age at hospitalisation (months) | |||||
| 0 | 15 | 9 | 1 | 3 | 1 |
| 1 | 14 | 13 | 1 | 11 | 2 |
| 2 | 9 | 10 | 6 | 8 | 2 |
| 3 | 4 | 8 | 3 | 5 | 1 |
| 4 | 4 | 5 | 1 | 3 | 1 |
| 5 | 5 | 1 | 2 | 0 | 0 |
| 6 | 2 | 4 | 0 | 3 | 0 |
| 7 | 2 | 1 | 1 | 2 | 0 |
| 8 | 0 | 1 | 1 | 1 | 0 |
| 0–3 | 42 | 40 | 11 | 27 | 6 |
| Nirsevimab immunisation | |||||
| Yes | 46 | 26 | 13 | 26 | 4 |
| Age at immunisation (months) | |||||
| 0 | 29 | 16 | 4 | 16 | 3 |
| 1 | 5 | 2 | 3 | 4 | 0 |
| 2 | 9 | 3 | 2 | 1 | 1 |
| 3 | 1 | 2 | 1 | 0 | 0 |
| 4 | 2 | 2 | 1 | 2 | 0 |
| 5 | 4 | 1 | 1 | 1 | 0 |
| 6 | 0 | 0 | 1 | 2 | 0 |
| 7 | 0 | 0 | 0 | 0 | 0 |
| 8 | 1 | 0 | 0 | 0 | 0 |
| Unknown | 4 | 26 | 3 | 10 | 3 |
| Month of hospitalisation | |||||
| Oct 2023 | 14 | 0 | 2 | 0 | 0 |
| Nov 2023 | 14 | 11 | 7 | 7 | 2 |
| Dec 2023 | 19 | 36 | 5 | 23 | 3 |
| Jan 2024 | 8 | 5 | 2 | 6 | 2 |
LRTI: lower respiratory tract infections; RSV: respiratory syncytial virus.